Biopharma companies continued to tap public and private markets in early 2026, with BioWorld’s running tallies tracking steady capital formation through early April and breaking out money raised by month. Over the April 1-10 period, daily roundups highlighted a mix of financings alongside clinical readouts, leadership and board changes, and other notable corporate developments, while regulators logged a steady cadence of approvals, filings and program updates. A separate Q1 2026 job market report pointed to ongoing recalibration in biopharma hiring as companies balance funding conditions with pipeline and commercialization needs. Find out more details in 41 news articles below.